Generic Medicine Info
Indications and Dosage
Upper gastrointestinal haemorrhage
Adult: 75 mg bid via slow inj or infusion.

Zollinger-Ellison syndrome
Adult: 75 mg bid.

Gastro-oesophageal reflux disease
Adult: 75 mg bid or 150 mg at bedtime for 6-8 wk.

Premedication before anaesthesia
Adult: 75 mg in the evening on the day before surgery and repeated 2 hr before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery.

Peptic ulcer
Adult: 150 mg at bedtime or 75 mg bid daily for 4-6 wk. Maintenance: 75 mg at bedtime.

Adult: 75 mg once daily in the evening.
Renal Impairment
Gastritis; Gastro-oesophageal reflux disease; Zollinger-Ellison syndrome; Peptic ulcer:
CrCl (mL/min) Dosage
<20 75 mg every 2 days.
 20-50 75 mg at bedtime.
Lactation. Porphyria.
Special Precautions
Renal and hepatic impairment, pregnancy. May mask the symptoms of gastric malignancy.
Adverse Reactions
Occasional headache, GI disturbances, gynaecomastia, alopecia, blood dyscrasias, pancreatitis, sleep disturbances, restlessness, rarely dizziness. Hypersensitivity reactions e.g. rash and itching reported occasionally. Changes in pulse rate and transient impairment of sexual drive. Possible increase in liver enzyme activity. May reduce leucocytes and/or thrombocytes.
Drug Interactions
May affect serum levels of protease inhibitors.
Mechanism of Action: Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action.
Absorption: Absorbed rapidly and almost completely from the GI tract (oral); peak plasma concentrations after 1-3 hr.
Distribution: Enters breast milk (small amounts).
Metabolism: Liver, small intestines and serum; hydrolysed to the desacetyl metabolite.
Excretion: Via urine (90% as roxatidine and metabolites); 6 hr (elimination half-life).
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
Disclaimer: This information is independently developed by MIMS based on Roxatidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in